These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 10666558)

  • 1. Dopamine-antagonistic, anticholinergic, and GABAergic effects on declarative and procedural memory functions.
    Rammsayer TH; Rodewald S; Groh D
    Brain Res Cogn Brain Res; 2000 Jan; 9(1):61-71. PubMed ID: 10666558
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dopamine Enhances Item Novelty Detection via Hippocampal and Associative Recall via Left Lateral Prefrontal Cortex Mechanisms.
    Clos M; Bunzeck N; Sommer T
    J Neurosci; 2019 Oct; 39(40):7920-7933. PubMed ID: 31405927
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cognitive and behavioral effects of cholinergic, dopaminergic, and serotonergic blockade in humans.
    Vitiello B; Martin A; Hill J; Mack C; Molchan S; Martinez R; Murphy DL; Sunderland T
    Neuropsychopharmacology; 1997 Jan; 16(1):15-24. PubMed ID: 8981385
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The effects of a benzodiazepine receptor antagonist beta-carboline ZK-93426 on scopolamine-induced impairment on attention, memory and psychomotor skills.
    Duka T; Ott H; Rohloff A; Voet B
    Psychopharmacology (Berl); 1996 Feb; 123(4):361-73. PubMed ID: 8867876
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Regional brain activity during shape recognition impaired by a scopolamine challenge to encoding.
    Rosier AM; Cornette L; Dupont P; Bormans G; Mortelmans L; Orban GA
    Eur J Neurosci; 1999 Oct; 11(10):3701-14. PubMed ID: 10564377
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Synergistic anticholinergic and antiserotonergic effects in humans.
    Meador KJ; Loring DW; Hendrix N; Nichols ME; Oberzan R; Moore EE
    J Clin Exp Neuropsychol; 1995 Aug; 17(4):611-21. PubMed ID: 7593479
    [TBL] [Abstract][Full Text] [Related]  

  • 7. GABAergic but not anti-cholinergic agents re-induce clinical deficits after stroke.
    Lazar RM; Berman MF; Festa JR; Geller AE; Matejovsky TG; Marshall RS
    J Neurol Sci; 2010 May; 292(1-2):72-6. PubMed ID: 20172537
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lorazepam and scopolamine: A single-dose comparison of effects on human memory and attentional processes.
    Mintzer MZ; Griffiths RR
    Exp Clin Psychopharmacol; 2003 Feb; 11(1):56-72. PubMed ID: 12622344
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Differential effects of striatal injections of dopaminergic, cholinergic and GABAergic drugs upon swimming behavior of rats.
    Vrijmoed-de Vries MC; Cools AR
    Brain Res; 1986 Jan; 364(1):77-90. PubMed ID: 3004649
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neuropharmacological evidence for different timing mechanisms in humans.
    Rammsayer TH
    Q J Exp Psychol B; 1999 Aug; 52(3):273-86. PubMed ID: 10467900
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Histamine H1-receptor blockade in humans affects psychomotor performance but not memory.
    van Ruitenbeek P; Vermeeren A; Riedel W
    J Psychopharmacol; 2008 Aug; 22(6):663-72. PubMed ID: 18208925
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetics and pharmacodynamics of scopolamine after subcutaneous administration.
    Ebert U; Siepmann M; Oertel R; Wesnes KA; Kirch W
    J Clin Pharmacol; 1998 Aug; 38(8):720-6. PubMed ID: 9725548
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Are there dissociable roles of the mesostriatal and mesolimbocortical dopamine systems on temporal information processing in humans?
    Rammsayer TH
    Neuropsychobiology; 1997; 35(1):36-45. PubMed ID: 9018022
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lack of amnestic, psychotomimetic or impairing effect on psychomotor performance of eliprodil, a new NMDA antagonist.
    Patat A; Molinier P; Hergueta T; Brohier S; Zieleniuk I; Danjou P; Warot D; Puech A
    Int Clin Psychopharmacol; 1994 Sep; 9(3):155-62. PubMed ID: 7814824
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cholinergic enhancement of episodic memory in healthy young adults.
    Grön G; Kirstein M; Thielscher A; Riepe MW; Spitzer M
    Psychopharmacology (Berl); 2005 Oct; 182(1):170-9. PubMed ID: 16021483
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Drugs, memory, and metamemory: a dose-effect study with lorazepam and scopolamine.
    Mintzer MZ; Griffiths RR
    Exp Clin Psychopharmacol; 2005 Nov; 13(4):336-47. PubMed ID: 16366764
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Acute dose-effects of scopolamine on false recognition.
    Mintzer MZ; Griffiths RR
    Psychopharmacology (Berl); 2001 Feb; 153(4):425-33. PubMed ID: 11243489
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Differentiating the effects of centrally acting drugs on arousal and memory: an event-related potential study of scopolamine, lorazepam and diphenhydramine.
    Curran HV; Pooviboonsuk P; Dalton JA; Lader MH
    Psychopharmacology (Berl); 1998 Jan; 135(1):27-36. PubMed ID: 9489931
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Modulation of memory and visuospatial processes by biperiden and rivastigmine in elderly healthy subjects.
    Wezenberg E; Verkes RJ; Sabbe BG; Ruigt GS; Hulstijn W
    Psychopharmacology (Berl); 2005 Sep; 181(3):582-94. PubMed ID: 16041534
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neutral and emotional episodic memory: global impairment after lorazepam or scopolamine.
    Kamboj SK; Curran HV
    Psychopharmacology (Berl); 2006 Nov; 188(4):482-8. PubMed ID: 17047934
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.